Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03294460 · ClinicalTrials.gov registry record · Phase 1

Nicotinic Receptor Genetic Variation and Alcohol Reward

A Phase 1 study of Alcohol Drinking, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
1
Study location

NCT03294460 is a Phase 1 study of Alcohol Drinking that is actively recruiting participants, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 128 participants, below the 629-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03294460, a Phase 1 study of Alcohol Drinking, is actively recruiting participants, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

Background: People with the brain disease AUD (alcohol use disorder) have a serious problem with drinking. Researchers want to study how different people react to alcohol, and how genes affect this. They will focus on a nicotine receptor gene that may increase a person s AUD risk. Objectives: To see if people with variations of a nicotine receptor gene take alcohol differently and have different brain responses to alcohol cues. Eligibility: Healthy adults ages 21 - 60. This study includes smokers and non-smokers. Design: Participation will be based on evaluation under the NIAAA natural history protocol (14-AA-0181) or a screening visit under this protocol. Participants will have two 9-hour visits. They must have no alcohol or non-prescription drugs before all visits and no food or drink before the first visit. At every visit, participants will: * Get a light meal * Have breath and urine tests * Get taxi rides there and back At visits 1, participants will: * Have a thin plastic tube inserted in an arm and connected to a pump for alcohol infusion. * Have sensors on their chest to monitor heart rate. * Sit in a chair for 2.5 hours and get alcohol by pushing a button. Their breath alcohol level will be monitored. * Answer questions about mood and effects of alcohol * Give blood samples * Relax at the clinic while their breath alcohol level drops At visit 2, participants will: * Answer questions and do computer tests * Have an alcoholic drink and a snack * Have a magnetic resonance imaging (MRI) scan. They will lie in a machine that takes pictures of the brain. They will do computer tasks. * Have another drink and snack * Relax until their alcohol level drops Participants will have a follow-up call after each visit.

Conditions Studied

Interventions

  • DRUG Alcohol (Oral)
  • DRUG Alcohol (IV)
  • DRUG Alcohol (Ethanol)

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2019-06-10
Est. Completion 2026-12-31
Phase Phase 1

What the Registry Record Tells You About NCT03294460

The ClinicalTrials.gov registry entry for NCT03294460 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 629-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (80% lower). The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Drinking appearing as the primary indexed condition, and to 3 interventions - of which Alcohol (Oral) is the first listed.

NCT03294460 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03294460 about?

NCT03294460 is a clinical study titled "Nicotinic Receptor Genetic Variation and Alcohol Reward". Background: People with the brain disease AUD (alcohol use disorder) have a serious problem with drinking. Researchers want to study how different people react to alcohol, and how genes affect this. They will focus on a nicotine receptor gene that may increase a person s AUD risk. Objectives: To ...

What is the current status of trial NCT03294460?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2019-06-10. Estimated completion is 2026-12-31.

What conditions does trial NCT03294460 study?

This clinical trial studies the following conditions: Alcohol Drinking.

What interventions are being tested in trial NCT03294460?

The interventions under investigation include: Alcohol (Oral) (DRUG), Alcohol (IV) (DRUG), Alcohol (Ethanol) (DRUG).

Who is sponsoring clinical trial NCT03294460?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03294460 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Drinking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.